Trademark Search in Canada

XENLETA

View On IC.GC.CA

REGISTERED

on 17 Feb 2025

Last Applicant/ Owned by

Nabriva Therapeutics US, Inc.

1000 Continental Drive, Suite 600 King of Prussia, Pennsylvania 19406

Serial Number

1985919 filed on 9^th Sept 2019

Registration Number

TMA1290471 registered on 17^th Feb 2025

Registration expiry Date

17^th Feb 2035

Correspondent Address

SMART & BIGGAR LP

Scotia Plaza, 40 King Street West40th FloorToronto

ONTARIO

M5H3Y2

XENLETA

Trademark usage description

pharmaceutical preparations for treating respiratory diseases; antibiotics; pharmaceutical preparations for the treatment of pneumonia and bacterial i Read More

Classification Information

Class [005]
Pharmaceutical preparations for treating respiratory diseases; antibiotics; pharmaceutical preparations for the treatment of pneumonia and bacterial infections, namely, community-acquired bacterial pneumonia (CABP).

Classification kind code

Mark Details

Serial Number

1985919

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 42 on 27^th Nov 2024	Advertised
Submitted for opposition 27 on 31^st Oct 2024	Approval Notice Sent
Submitted for opposition 26 on 31^st Oct 2024	Approved
Submitted for opposition 22 on 15^th Apr 2024	Search Recorded
Submitted for opposition 20 on 15^th Apr 2024	Examiner's First Report
Submitted for opposition 67 on 7^th Oct 2022	Agent Name Changed
Submitted for opposition 287 on 13^th Apr 2022	Pre-Assessment Letter Sent
Submitted for opposition 31 on 20^th Sept 2019	Formalized
Submitted for opposition 1 on 19^th Sept 2019	Created
Submitted for opposition 30 on 9^th Sept 2019	Filed

XENLETA

Classification Information

Class [005]Pharmaceutical preparations for treating respiratory diseases; antibiotics; pharmaceutical preparations for the treatment of pneumonia and bacterial infections, namely, community-acquired bacterial pneumonia (CABP).

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceutical preparations for treating respiratory diseases; antibiotics; pharmaceutical preparations for the treatment of pneumonia and bacterial infections, namely, community-acquired bacterial pneumonia (CABP).